Sources

7 Total Sources

Eli Lilly Says Retatrutide Shows No Added Heart Risk in Obesity Study as Review Nears

Left33%

Center67%

Bloomberg21h ago

Eli Lilly's Retatrutide Weight-Loss Shot Shows No Increased Heart Risk in New Study

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application | Reuters

StockTitan21h ago

Eli Lilly Retatrutide Phase 3: Up to 22.6% Weight Loss | LLY Stock News

Straight Arrow News21h ago

Eli Lilly touts strong results of new experimental weight loss drug retatrutide

Eli Lilly presents positive safety data but postpones weight-loss candidate application

Instagram21h ago

The biggest retatrutide headline may not be the weight loss. It may be the word “biologic.” Lilly says it plans to submit retatrutide through a Biologics License Application, or BLA, in Q1

excelmale.com21h ago

Retatrutide (GLP-3): Real Dosing, Results & Side Effects